Skip to main content

Table 1 Patient characteristics

From: Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors

Characteristic Everolimus 5 mg/day
(n = 12)
Everolimus 10 mg/day
(n = 12)
Median (range) age, y 55 (27-75) 56 (32-75)
Sex, n (%)   
   Male 5 (41.7) 4 (33.3)
   Female 7 (58.3) 8 (66.7)
WHO performance status, n (%)   
   0 3 (25.0) 1 (8.3)
   1 9 (75.0) 9 (75.0)
   2 0 2 (16.7)
Prior antineoplastic therapy, n (%)   
   Surgery 11 (91.7) 10 (83.3)
   Radiotherapy 3 (25.0) 3 (25.0)
   Chemotherapy 10 (83.3) 10 (83.3)
   Targeted therapy 5 (41.7) 5 (41.7)
   Immunotherapy 3 (25.0) 2 (16.7)
   Hormonal therapy 2 (16.7) 0
  1. WHO = World Health Organization.